Key facts
- Notable investors include Jiangsu Yuyue Medical, Zhenzhuo Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ancocare
- ·The full record, as it builds
Funding rounds
No funding rounds for Ancocare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ancocare
Developer of gene-based therapeutic agents intended for immuno-oncology and rare disease applications. The company offers proprietary virus-vector modular technology with dual-targeting and dual-signaling mechanisms to induce long-lasting immune responses, serving the biopharmaceutical market to address limitations in current immunotherapies by enhancing tumor-specific immune activation, improving treatment durability, and expanding therapeutic coverage across multiple cancer types.
- Sector
- Healthcare
- HQ
- Sichuan, China
- Founded
- 2018
- Employees
- 4
- Website
- ancocare.com/
- Ownership
- Privately Held (backing)
Ancocare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ancocare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ancocare in its N-PORT filings yet. We sweep new filings monthly.